Toxicological and Pharmacological Profile of Amanita muscaria: A Rising Opportunity for Biomedicine

Toxicological and Pharmacological Profile of Amanita muscaria: A Rising Opportunity for Biomedicine

Introduction

Amanita muscaria, commonly known as fly agaric, is a basidiomycete mushroom with a rich history and a wide range of pharmacological and toxicological properties. This review aims to explore the morphology, chemical content, toxicological and pharmacological characteristics, and potential uses of Amanita muscaria in modern medicine.

Morphology and Distribution

Amanita muscaria belongs to the Amanita genus and is distributed worldwide, primarily in conifer and deciduous woodlands of the Northern Hemisphere. The cap of A. muscaria can range in color from orange to yellow, with some populations exhibiting consistently yellow or white caps. The gills are narrow and white, and the stipe has a skirt-like annulus and a variable-shaped bulb.

Chemical Composition

Amanita muscaria contains several bioactive compounds, including ibotenic acid, muscimol, muscarine, and various pigments. Ibotenic acid is converted to muscimol in the body and is responsible for the mushroom's hallucinogenic effects. Muscarine is a cholinergic agonist that contributes to the overall activity of A. muscaria. The pigments in A. muscaria give the mushroom its characteristic red-orange color.

Toxicological Effects

Consuming Amanita muscaria can lead to a condition known as 'pantherina-muscaria' poisoning syndrome, which resembles alcoholic intoxication. Symptoms include dizziness, nausea, tiredness, visual and auditory hypersensitivity, hallucinations, and altered perception of time. The toxicity of A. muscaria is primarily attributed to the neurotoxic effects of ibotenic acid and muscimol.

Pharmacological Potential

Despite its toxic effects, Amanita muscaria has also shown potential pharmacological benefits. Some studies suggest that A. muscaria extracts may have a neuroprotective role in neurodegenerative diseases such as Parkinson's and Alzheimer's. The mushroom has also demonstrated a potent role in the treatment of cerebral ischemia and other socially significant health conditions.

Conclusion

Amanita muscaria offers a wide range of pharmacological and toxicological properties, making it a promising candidate for biomedical research. Its potential neuroprotective, anticarcinogenic, and antioxidant effects warrant further investigation. However, the toxic effects of A. muscaria emphasize the need for careful administration and supervision. Mycotherapy, the use of mushrooms for therapeutic purposes, holds great potential for the development of new drugs and treatment strategies in the future.

References

  • Bas C (1969) Morphology and subdivision of Amanita and a monograph on its section Lepidella. Persoonia 5(4): 285–579.
  • Benjamin D (1992) Mushroom poisoning in infants and children: The Amanita Pantherina/Muscaria group. Journal of Toxicology: Clinical Toxicology 30(1): 13–22.
  • Chilton W, Hsu C, Zdybac W (1974) Stizolobic and stizolobinic acids in Amanita pantherina. Phytochemistry 13(7): 1179–1181.
  • Conrad C, Jackson J, Wise L (2004) Chronic stress enhances ibotenic acid-induced damage selectively within the hippocampal CA3 region of male, but not female rats. Neuroscience 125(3): 759–767.
  • Corcoran K, Maren S (2001) Hippocampal inactivation disrupts contextual retrieval of fear memory after extinction. The Journal of Neuroscience 21(5): 1720–1726.
  • De Carolis A, Lipparini F, Longo V (1969) Neuropharmacological investigations on muscimol, a psychotropic drug extracted from Amanita muscaria. Psychopharmacologia 15(3): 186–195.
  • De Feudis F (1980) Physiological and behavioral studies with muscimol. Neurochemical Research 5(10): 1047–1068.
  • Dunk C, Lebel T, Keane P (2011) Characterisation of ectomycorrhizal formation by the exotic fungus Amanita muscaria with Nothofagus cunninghamii in Victoria, Australia. Mycorrhiza 22(2): 135–147.
  • Eugster CH (1979) Isolation, structure and synthesis of central active compounds from Amanita muscaria (L. ex Fr.) Hooker. In: Efron D, Holmstedt B, Kline N (Eds) Ethnopharmacologic Search for Psychoactive Drugs. Public Health Service Publication Number 1645: 416–419.
  • Eugster C, Müller G, Good R (1965) Wirkstoffe aus Amanita muscaria: ibotensaeure und muscazon. Tetrahedron Letters 6(23): 1813–1815.
  • Feeney K (2010) Revisiting Wasson’s Soma: Exploring the effects of preparation on the chemistry of Amanita muscaria. Journal of Psychoactive Drugs 42(4): 499–506.
  • Food and Drug Administration (2012) Bad Bug Book, Foodborne pathogenic microorganisms and natural toxins. Second edn. Mushroom toxins: 218 pp.
  • Fritz H, Gagneux A, Zbinden R, Geigy J, Basle S, Eugster C (1965) The structure of muscazone. Tetrahedron Letters 6(25): 2075–2076.
  • Geddes J, Chang-Chui H, Cooper S, Lott L, Cotman C (1986) Density and distribution of NMDA receptors in the human hippocampus in Alzheimer’s disease. Brain Research 399(1): 156–161.
  • Geml J, Tulloss R, Laursen G, Sazanova N, Taylor D (2008) Evidence for strong inter- and intracontinental phylogeographic structure in Amanita muscaria, a wind-dispersed ectomycorrhizal basidiomycete. Molecular Phylogenetics and Evolution 48(2): 694–701.
  • Johnston G, Chebib M, Duke R, Fernandez S, Hanrahan J, Hinton T, Mewett K (2019) Herbal products and GABA receptors. Encyclopedia of Neuroscience: 1095–1101.

  • Tatsuta M, Iishi H, Baba M, Nakaizumi A, Taniguchi H (1992) Effects of muscimol on enhancement of gastric carcinogenesis in spontaneously hypertensive rats. Japanese Journal of Cancer Research 83(9): 909–912.
  • Voynova M et al.: Toxicological and pharmacological profile of Amanita muscaria. Pharmacia 67(4): 317–323.
    Volver al blog

    Amanita Muscaria Tinctures